GlassScriptPhysician profile
Sheila Maier
NPI 1033599162
$2,387.29
in general payments reported to CMS, 2019-2025
23 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.34 · 2021: $130 · 2022: $67.72 · 2023: $486 · 2024: $977 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $496.65 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Lilly USA, LLC | $325.94 | 2021-2025 | Mounjaro, Zepbound, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.52 | 2023-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $195.49 | 2023-2025 | Benlysta |
| Abbott Laboratories | $156.02 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $146.45 | 2021-2025 | Rybelsus, Ozempic |
| Fresenius Kabi USA, LLC | $124.72 | 2023-2025 | Idacio, Tyenne |
| E.R. Squibb & Sons, L.L.C. | $112.98 | 2024-2025 | Orencia |
| Xeris Pharmaceuticals, INC. | $105.88 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $85.69 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $76.70 | 2023-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $55.66 | 2024-2025 | |
| Dexcom, INC. | $51.54 | 2023-2024 | Dexcom G6 Transmitter |
| Sandoz INC. | $39.99 | 2024 | Hyrimoz |
| Janssen Biotech, INC. | $34.77 | 2025 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.81 | 2025 | Saphnelo |
| Sequel Med Tech, LLC | $26.00 | 2025 | Twiist |
| Vertex Pharmaceuticals Incorporated | $25.17 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.73 | 2023 | |
| Ucb, INC. | $21.71 | 2024 | Cimzia |
| Genzyme Corporation | $20.37 | 2023 | |
| Insulet Corporation | $14.16 | 2023 | Omnipod |
| Medtronic Minimed, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Maier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.